Loperfido S, Angelini G, Benedetti G, Chilovi F, Costan F, De Berardinis F, De Bernardin M, Ederle A, Fina P, Fratton A
S.I.E.D. (Italian Society for Digestive Endoscopy) Triveneto Study Group on ERCP Complications: Ospedali di Treviso, Italy.
Gastrointest Endosc. 1998 Jul;48(1):1-10. doi: 10.1016/s0016-5107(98)70121-x.
There is a lack of multicenter prospective studies on complications of diagnostic and therapeutic endoscopic retrograde cholangiopancreatography (ERCP).
We studied 2769 consecutive patients undergoing ERCP at nine centers in the Triveneto region of Italy over a 2-year period. Six centers performed ERCP on less than 200 patients per year (small centers). General and ERCP-specific major complications were predefined. Data were collected at the time of ERCP, before discharge, and in cases of readmission within 30 days. ERCP was defined as therapeutic when endoscopic sphincterotomy (n = 1583), precut (n = 419), or drainage (n = 701) had been carried out, singularly or in combination.
One hundred eleven major complications (4.0%) were recorded: moderate-severe pancreatitis 36 (1.3%), cholangitis 24 (0.87%), hemorrhage 21 (0.76%), duodenal perforation 16 (0.58%), others 14 (0.51%). Among 942 diagnostic ERCPs there were 13 major complications (1.38%) and 2 deaths (0.21%), whereas among 1827 therapeutic ERCPs there were 98 major complications (5.4%) and 9 deaths (0.49%). The difference in the incidence of complications between diagnostic and therapeutic ERCPs was statistically significant (p < 0.0001). Small center and precut were recognized as independent risk factors for overall major complications of therapeutic ERCP, whereas the following risk factors were identified in relation to specific complications: (1) pancreatitis: age less than 70 years, pancreatic duct opacification, and nondilated common bile duct; (2) cholangitis: small center, jaundice; (3) hemorrhage: small center; and (4) retroperitoneal duodenal perforation: precut, intramural injection of contrast medium, and Billroth II gastrectomy.
Major complications are mostly associated with therapeutic procedures and low case volume. Present data support a policy of centralization of ERCP in referral centers. A more selected and safer use of precut may be expected to further limit the adverse events of ERCP.
目前缺乏关于诊断性和治疗性内镜逆行胰胆管造影术(ERCP)并发症的多中心前瞻性研究。
我们对意大利特里维内托地区9个中心在2年期间连续接受ERCP的2769例患者进行了研究。6个中心每年进行ERCP的患者少于200例(小中心)。预先定义了一般和ERCP特异性的主要并发症。在ERCP时、出院前以及30天内再次入院的情况下收集数据。当进行内镜括约肌切开术(n = 1583)、预切开术(n = 419)或引流术(n = 701)单独或联合进行时,ERCP被定义为治疗性的。
记录到111例主要并发症(4.0%):中度至重度胰腺炎36例(1.3%)、胆管炎24例(0.87%)、出血21例(0.76%)、十二指肠穿孔16例(0.58%)、其他14例(0.51%)。在942例诊断性ERCP中,有13例主要并发症(1.38%)和2例死亡(0.21%),而在1827例治疗性ERCP中,有98例主要并发症(5.4%)和9例死亡(0.49%)。诊断性和治疗性ERCP并发症发生率的差异具有统计学意义(p < 0.0001)。小中心和预切开术被认为是治疗性ERCP总体主要并发症的独立危险因素,而与特定并发症相关的危险因素如下:(1)胰腺炎:年龄小于70岁、胰管显影和未扩张的胆总管;(2)胆管炎:小中心、黄疸;(3)出血:小中心;(4)腹膜后十二指肠穿孔:预切开术、壁内注射造影剂和毕Ⅱ式胃切除术。
主要并发症大多与治疗性操作和低病例量相关。目前的数据支持将ERCP集中在转诊中心进行的政策。预期更有选择性和更安全地使用预切开术可能会进一步限制ERCP的不良事件。